VR Logo

Compass Therapeutics Inc. (CMPX) download report


Healthcare | Biotechnology & Pharma Research

Compass Therapeutics Inc. (CMPX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases.

IPO Date: 05-Apr-2021

Co-Founder, CEO & Director: Dr. Thomas J. Schuetz M.D., Ph.D.

Pres & COO: Dr. Vered Bisker-Leib MBA, Ph.D.

Listing: NASDAQ: CMPX

Country: United States

Headquarters: Boston, MA

Website: https://www.compasstherapeutics.com

Key Facts

Market cap: $283.60 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-81.92 Mln

Cash: $136.38 Mln

Total Debt: $3.77 Mln

Insider's Holding: 10.83%

Liquidity: Low

52 Week range: $1.25 - 5.80

Shares outstanding: 101,284,000

Stock Performance

Time Period Compass Therapeutics (CMPX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-13.56-9.04-17.14
1 month-8.67-3.46-4.85
3 months101.47-7.63-12.74
1 Year-44.080.12-16.37
3 Years--10.217.97
5 Years--11.356.33
10 Years--12.0610.54
As on 27-Jun-2022 *As on 28-Jun-2022